Clinical trial reveals no significant changes in cardiac vagal activity after transcutaneous auricular vagus nerve stimulation in HIV-positive men, suggesting further research is needed.
This proof-of-concept study evaluated the acute effects of transcutaneous auricular vagus nerve stimulation (taVNS) on cardiac vagal activity in people living with HIV. Twenty-one men living with HIV on antiretroviral therapy participated in a single-blind, crossover clinical trial. Participants underwent two counterbalanced stimulation conditions (taVNS and sham) with a 48-hour washout period. Cardiac vagal activity was assessed using vagally-mediated heart rate variability (vmHRV) indices, including the root mean square of successive differences (rMSSD) and the percentage of differences between adjacent normal intervals greater than 50 ms (pNN50), recorded before, during, and after stimulation. No significant changes in vmHRV parameters were observed over time or between conditions. These findings suggest that an acute taVNS session does not modulate cardiac vagal activity in people living with HIV. We discuss potential explanations for these results and highlight considerations for future research on taVNS as a non-pharmacological approach to autonomic modulation. Brazilian registry of clinical trials RBR-8k54cz.
No takes yet. Share an insight, caveat, or question.
Medeiros et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: